open access

Vol 70, No 6 (2019)
Clinical vignette
Submitted: 2019-07-31
Accepted: 2019-09-05
Early publication date: 2019-10-23
Get Citation

Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor

Edyta Cichocka1, Janusz Gumprecht1
DOI: 10.5603/EP.a2019.0047
·
Pubmed: 31681978
·
Endokrynol Pol 2019;70(6):522-523.
Affiliations
  1. School of Medicine with the Division of Dentistry in Zabrze, Medical University of Silesia, Katowice, Poland, Department of Internal Medicine, Diabetology, and Nephrology

open access

Vol 70, No 6 (2019)
Clinical Vignette
Submitted: 2019-07-31
Accepted: 2019-09-05
Early publication date: 2019-10-23

Abstract

Not available

Abstract

Not available
Get Citation

Keywords

weight loss; diabetes; SGLT-2 inhibitor

About this article
Title

Excess weight loss in a patient with type 2 diabetes mellitus treated with an SGLT-2 inhibitor

Journal

Endokrynologia Polska

Issue

Vol 70, No 6 (2019)

Article type

Clinical vignette

Pages

522-523

Early publication date

2019-10-23

Page views

1100

Article views/downloads

621

DOI

10.5603/EP.a2019.0047

Pubmed

31681978

Bibliographic record

Endokrynol Pol 2019;70(6):522-523.

Keywords

weight loss
diabetes
SGLT-2 inhibitor

Authors

Edyta Cichocka
Janusz Gumprecht

References (5)
  1. Diabetology C. 2018 Guidelines on the management of diabetic patients. A position of Diabetes Poland. Clin Diabet. 2018; 7(1): 1–90.
  2. Chao EC. SGLT-2 Inhibitors: A New Mechanism for Glycemic Control. Clin Diabetes. 2014; 32(1): 4–11.
  3. Cai X, Yang W, Gao X, et al. The Association Between the Dosage of SGLT2 Inhibitor and Weight Reduction in Type 2 Diabetes Patients: A Meta-Analysis. Obesity (Silver Spring). 2018; 26(1): 70–80.
  4. Thewjitcharoen Y, Yenseung N, Malidaeng A, et al. Effectiveness of long-term treatment with SGLT2 inhibitors: real-world evidence from a specialized diabetes center. Diabetol Metab Syndr. 2017; 9: 96.
  5. Ferrannini G, Hach T, Crowe S, et al. Energy Balance After Sodium-Glucose Cotransporter 2 Inhibition. Diabetes Care. 2015; 38(9): 1730–1735.

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl